Copeptin is a sensitive and more stable surrogate marker for arginine vasopressin. In this study, we evaluated copeptin levels in carotid endarterectomy (CEA) patients, perioperatively, to determine whether copeptin levels can be related to carotid artery cross clamping (CC) time and to postoperative neurological outcomes. Copeptin, interleukin 6, C-reactive protein, cortisol, and brain natriuretic peptide were measured preoperatively (T1) and 3 hours postoperatively (T3) as well as intraoperatively (T2). We recruited 77 patients. Values of copeptin rose gradually over the observed times: T1 = 7.9 (6.4-9.6), T2 = 12.6 (9.3-16.8), and T3 = 72.3 (49.1-111.2) pmol/L. There was a significant difference for repeated measurement (P = .000, P = .000, and P = .000). Duration of carotid artery CC during CEA does not affect postoperative copeptin level (CC ≤ 13 minutes: 106.8 ± 93.6 pmol/L, CC > 13 minutes: 96.7 ± 89.1 pmol/L; P = .634). Preoperative copeptin level was significantly higher in patients with ulcerated plaque morphology. Activation of the stress axis in patients undergoing CEA results in copeptin elevation. Duration of CC during CEA does not affect postoperative copeptin levels.
FassbenderKSchmidtRMossnerRDaffertshoferMHennericiM. Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke. 1994;25(6):1105–1108.
2.
OlssonTMarklundNGustafsonYNasmanB. Abnormalities at different levels of the hypothalamic-pituitary-adrenocortical axis early after stroke. Stroke. 1992;23(11):1573–1576.
3.
JohanssonAOlssonTCarlbergBKarlssonKFagerlundM. Hypercortisolism after stroke—partly cytokine-mediated?J Neurol Sci. 1997;147(1):43–47.
4.
ItoiKJiangYQIwasakiYWatsonSJ. Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol. 2004;16(4):348–355.
5.
AsfarPHauserBRadermacherPMatejovicM. Catecholamines and vasopressin during critical illness. Crit Care Clin. 2006;22(1):131–149, vii-viii.
6.
BolignanoDCabassiAFiaccadoriE. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med. 2014;52(10):1447–1456.
7.
MorgenthalerNGStruckJJochbergerSDunserMW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008;19(2):43–49.
8.
KatanMFluriFMorgenthalerNG. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009;66(6):799–808.
9.
AmeliPAAmeliNJGubernickDM. Role of vasopressin and its antagonism in stroke related edema. J Neurosci Res. 2014;92(9):1091–109.
10.
StruckJMorgenthalerNGBergmannA. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides. 2005;26(12):2500–2504.
11.
MorgenthalerNGStruckJAlonsoCBergmannA. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112–119.
12.
NickelCHBingisserRMorgenthalerNG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med. 2012;10(7):7.
13.
ZhangXLuXMHuangLFYeH. Copeptin is associated with one-year mortality and functional outcome in patients with acute spontaneous basal ganglia hemorrhage. Peptides. 2012;33(2):336–341.
14.
ZweifelCKatanMSchuetzP. Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurol. 2010;10:34.
15.
DongXQHuangMYangSBYuWHZhangZY. Copeptin is associated with mortality in patients with traumatic brain injury. J Trauma. 2011;71(5):1194–1198.
VakiliAKataokaHPlesnilaN. Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2005;25(8):1012–1019.
21.
Maravic-StojkovicVLausevic-VukLJObradovicM. Copeptin level after carotid endarterectomy and perioperative stroke. Angiology. 2014;65(2):122–129.
22.
PalomboDLucertiniGMambriniSZettinM. Subtle cerebral damage after shunting vs non shunting during carotid endarterectomy. Eur J Vasc Endovasc Surg. 2007;34(5):546–551.
23.
YoshidaKKurosakiYFunakiT. Surgical dissection of the internal carotid artery under flow control by proximal vessel clamping reduces embolic infarcts during carotid endarterectomy. World Neurosurg. 2014;82(1-2):e229–e234.
24.
DragasMKoncarIOpacicD. Fluctuations of serum neuron specific enolase and protein S-100B concentrations in relation to the use of shunt during carotid endarterectomy. PLoS One. 2015;10(4):e0124067.
25.
ParssonHNLordRSScottKZemackG. Maintaining carotid flow by shunting during carotid endarterectomy diminishes the inflammatory response mediating ischaemic brain injury. Eur J Vasc Endovasc Surg. 2000;19(2):124–130.
26.
CataJPAbdelmalakBFaragE. Neurological biomarkers in the perioperative period. Br J Anaesth. 2011;107(6):844–858.
27.
KvetnanskyRSabbanELPalkovitsM. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol Rev. 2009;89(2):535–606.
28.
De MarchisGMWeckAAudebertH. Copeptin for the prediction of recurrent cerebrovascular events after transient ischemic attack: results from the CoRisk study. Stroke. 2014;45(10):2918–2923.
29.
KatanMChrist-CrainM. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly. 2010;140:w13101.
30.
OstergaardLRudigerAWellmannS. Arginine-vasopressin marker copeptin is a sensitive plasma surrogate of hypoxic exposure. Hypoxia. 2014;2:143–151.
31.
JuddAMCallGBBarneyM. Possible function of IL-6 and TNF as intraadrenal factors in the regulation of adrenal steroid secretion. Ann N Y Acad Sci. 2000;917:628–637.
32.
Marrocco-TrischittaMMTiezziASvampaMG. Perioperative stress response to carotid endarterectomy: the impact of anesthetic modality. J Vasc Surg. 2004;39(6):1295–304.
33.
MussackTHauserCKlaussV. Serum S-100B protein levels during and after successful carotid artery stenting or carotid endarterectomy. J Endovasc Ther. 2006;13(1):39–46.
34.
HeoSHChoCHKimHO. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol. 2011;7(2):69–76.
35.
KisialiouAPeloneGCarrizzoA. Blood biomarkers role in acute ischemic stroke patients: higher is worse or better?Immun Ageing. 2012;9(1):22.
36.
RautouPEVionACAmabileN. Microparticles, vascular function, and atherothrombosis. Circ Res. 2011;109(5):593–606.
37.
MohlerJLMichaelKAFreedmanAMGriffenWOJrMcRobertsJW. The serum and urinary cortisol response to operative trauma. Surg Gynecol Obstet. 1985;161(5):445–449.
UdelsmanRNortonJAJelenichSE. Responses of the hypothalamic-pituitary-adrenal and renin-angiotensin axes and the sympathetic system during controlled surgical and anesthetic stress. J Clin Endocrinol Metab. 1987;64(5):986–994.
40.
KatanMMorgenthalerNWidmerI. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett. 2008;29(3):341–346.
41.
BercziIQuintanar-StephanoAKovacsK. Neuroimmune regulation in immunocompetence, acute illness, and healing. Ann N Y Acad Sci. 2009;1153:220–239.
42.
GanterUArconeRToniattiCMorroneGCilibertoG. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 1989;8(12):3773–3779.
43.
LiapisCDBellPFMikhailidisDP. ESVS guidelines: section A—prevention in patients with carotid stenosis. Curr Vasc Pharmacol. 2010;8(5):673–681.
44.
ParaskevasKIWierzbickiASMikhailidisDP. Statins and noncardiac vascular disease. Curr Opin Cardiol. 2012;27(4):392–397.
45.
GabayCKushnerI. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–454.
46.
HallidayAMansfieldAMarroJ. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet. 2004;363(9420):1491–1502.
47.
FergusonGGEliasziwMBarrHW. The North American symptomatic carotid endarterectomy trial: surgical results in 1415 patients. Stroke. 1999;30(9):1751–1758.
48.
GroupSCRinglebPAAllenbergJ. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet. 2006;368(9543):1239–1247.
49.
YoungBMooreWSRobertsonJT. An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS investigators. Asymptomatic carotid atherosclerosis study. Stroke. 1996;27(12):2216–2224.
50.
AbuRahmaAFKhanJHRobinsonPA. Prospective randomized trial of carotid endarterectomy with primary closure and patch angioplasty with saphenous vein, jugular vein, and polytetrafluoroethylene: perioperative (30-day) results. J Vasc Surg. 1996;24(6):998–1006; discussion 1006-1007.
51.
AbuRahmaAFRobinsonPASaiedySKahnJHBolandJP. Prospective randomized trial of carotid endarterectomy with primary closure and patch angioplasty with saphenous vein, jugular vein, and polytetrafluoroethylene: long-term follow-up. J Vasc Surg. 1998;27(2):222–232; discussion 233-234.
52.
BondRRerkasemKNaylorARAburahmaAFRothwellPM. Systematic review of randomized controlled trials of patch angioplasty versus primary closure and different types of patch materials during carotid endarterectomy. J Vasc Surg. 2004;40(6):1126–1135.
